Myriad Genetics Inc (LTS:0K3W)
$ 13.635 0.293 (2.19%) Market Cap: 1.24 Bil Enterprise Value: 1.29 Bil PE Ratio: 0 PB Ratio: 1.70 GF Score: 63/100

Myriad Genetics Inc at Bank of America Merrill Lynch Health Care Conference Transcript

May 15, 2019 / 08:40PM GMT
Release Date Price: $27.45
Xiaoxiao Ma
BofA Merrill Lynch, Research Division - Associate

Well, great to have our next session here with Myriad. We have CEO (sic) [CFO], Bryan, and Scott from the IR joining us today. Great to have you guys. Well, on behalf of my senior analyst, Derik De Bruin, just wanted to give everyone greeting for and thank you for being here.

Without further ado, let's have Bryan give us a brief outline and recap the quarter maybe.

R. Bryan Riggsbee
Myriad Genetics, Inc. - Executive VP, CFO & Treasurer

Great. Thanks, Ivy. Thank you for hosting. We really appreciate the opportunity to be here.

First of all, at Myriad, we're really focused on 5 strategic priorities. The first of those is to create a stable hereditary cancer business and maintain a stable business. We believe we made great strides there. We've had 2 consecutive quarters of 4% year-over-year growth, which I think the first one was the first time in 4 or 5 years that we had seen that business grow on a year-over-year basis. And we've increasingly seen positive signs in that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot